

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

EP V. 10.03.04

D3

18981 EP1
109
Vd

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, 1/70	A1	(11) International Publication Number: WO 00/29613
		(43) International Publication Date: 25 May 2000 (25.05.00)
<p>(21) International Application Number: PCT/EP99/08847</p> <p>(22) International Filing Date: 17 November 1999 (17.11.99)</p> <p>(30) Priority Data: MI98A002491 17 November 1998 (17.11.98) IT</p> <p>(71) Applicant (for all designated States except US): FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): LOCATELLI, Giuseppe [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). LUSSO, Paolo [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). MALNATI, Mauro [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). SALVATORI, Francesca [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT). SCARLATTI, Gabriella [IT/IT]; Via Olgettina, 58, I-20132 Milano (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(54) Title: METHOD FOR THE QUANTITATIVE DETECTION OF NUCLEIC ACIDS		
<p>(57) Abstract</p> <p>Provided herein is a method for the quantitative detection of nucleic acids based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5'-3' nuclease activity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR THE QUANTITATIVE DETECTION OF NUCLEIC
ACIDS

The present invention relates to a method for quantitative detection of nucleic acids from a biological fluid sample.

The method of the invention may be suitably applied to diagnosis of viral and any other pathogenic agents and to monitor safety and/or genetic
5 composition of waters, foods and plant species used in the alimentary field.

BACKGROUND ART

A commonly used strategy to detect the presence of pathogens, in biological fluids, is the detection of an antigen (direct method) or a
10 respective antibody (indirect method). However, this strategy, performed with immunometric techniques such as ELISA, IFA or Western Blotting, is limited because of the scarce quantitation accuracy, precision and sensitivity, of the different antibody cross-reactivity and of the impossibility to obtain precocious diagnosis.

15 Another approach relies on the detection of nucleic acids specific for each kind of molecular target from any biological source, using the amplification by polymerase chain reaction (PCR). This technique, in its more sophisticated version i.e. the quantitative competitive PCR (qcPCR), makes it possible to reach a high sensitivity and a quite accurate
20 quantitative measure, as well as to obtain a diagnosis a short time after contact between the patient and the pathogen. Nevertheless the precision and accuracy of this system is assured in a narrow quantitation range, thus forcing the operator to multiply the number of replies (typically 8) of the sample under investigation; furthermore a long time and additional costs

CONFIRMATION COPY

for the amplified product detection steps are necessary.

The first systems that assessed PCR kinetics in real time were based on an intercalating substance such as ethidium bromide. This substance binds to the polymerizing double strand DNA proportionally, enhancing its fluorescence in response to UV excitation; the fluorescence emitted from the intercalated ethidium molecules was registered by a CCD camera in a thermal cycler equipped to irradiate the samples with UV rays and plotted against the amplification cycle number (Higuchi et al., Biotechnology 10:413-417). The main limitation of this technique is that the signal is generated also from the unspecific PCR products.

Subsequently the method known as TaqMan, described in US 5210015 was introduced. This method is based on the real time detection of the fluorescence deriving from the degradation, directly dependent on the nascent PCR product, of a labeled probe specifically hybridizing to the segment to amplify, by means of the Taq polymerase enzyme. The PCR reaction mix contains a non-extendable oligonucleotide probe, labeled with two fluorescent molecules, a reporter at the 5' end, and a quencher at the 3' end; the probe sequence must be complementary to a region of the DNA under investigation located between the two annealing sites of the oligonucleotide primers.

During the PCR amplification reaction, the Taq Polymerase enzyme specifically activated by the primers starts duplicating the DNA under investigation; when the enzyme contacts the probe annealed to the DNA, cuts it by its 5' nuclease activity, removing it and consequently separating the fluorescent molecules; the emission from the reporter fluorochrome becomes thus measurable and, each DNA molecule being accompanied by a reporter molecule release, the total fluorescence is at any time

proportional to the amplified DNA amount. The Sequence Detection System 7700 ABI PRISM (produced and distributed by Perkin Elmer) can work both as a DNA amplifier and a collector of fluorescence signals from samples during the PCR reaction. These signals are then processed
5 by a software capable of extrapolating the starting DNA amount in the analyzed samples by a standard curve built with the fluorescence signals from samples with known DNA content. It must be noted that such a system is endowed with two specificity levels: the specific annealing of the primers and the specific annealing of the probe.

10 SUMMARY OF THE INVENTION

A method generally applicable to the nucleic acid quantitation techniques based on the polymerase and 5' nuclease activity of nucleic acid polymerases, improving the efficiency of the techniques themselves, along with an enhanced sensitivity, accuracy and precision and a reduced
15 measure variability, has now been found.

The method of the invention is based on the use of a calibrator during the steps of extraction of the sample, of target nucleic acid amplification and subsequent detection with suitable probes able to differentially hybridize to the calibrator and the target sequence.

20 The method of the invention can be applied to any absolute quantitation of nucleic acids from different biological sources, for example to the quantitation of viral or bacterial pathogens in body liquids (liquor, urine, plasma, serum, synovial fluid) or to the quantitation of environmental or food contaminants.

25 DETAILED DESCRIPTION OF THE INVENTION

Nucleic acid quantitation techniques, using the polymerase and 5' nuclease activity of the nucleic acid polymerases, rely on the extraction of

nucleic acid from the sample, on the preparation of a reaction mix containing a polymerase, primers specific for the target sequence and a probe specific for a target sequence included between the regions complementary to the two primers, said probe being labeled with a reporter (this reporter being preferably a fluorochrome) and a quencher, followed by determination of the signal from the reporter label released when the polymerase contacts the 5' end of the probe annealed to the target nucleic acid.

According to the method of the invention, a known amount of the template nucleic acid, hereafter referred to as calibrator, is added to the sample before the extraction of the nucleic acid to be quantitatively detected (target nucleic acid). The calibrator has a sequence identical to the target nucleic acid sequence with the exception of one or more regions whose sequence is different from the corresponding regions of the target nucleic acid, having with respect to the latter a randomized sequence and a similar T_m . More specifically, one of those different regions must be the region complementary to the probe, with a T_m comprised in the range of $\pm 4^\circ\text{C}$ the T_m of the target nucleic acid, preferably in the range ± 2 . The other different regions of the calibrator may be those annealing with the primers, which have randomized sequences with respect to the target nucleic acid and a T_m comprised in the range of $\pm 1^\circ\text{C}$ the T_m of the target nucleic acid.

When this second embodiment is provided, i.e. when the calibrator regions complementary to the primers are varied with respect to the target nucleic acid, in addition to the regions complementary to the probe, it is possible to extremely reduce the competition events occurring between the target template and the calibrator, and to simultaneously measure the

target template and the calibrator in a single reaction tube.

After extraction, the primers, and separately the probes derivatized with a reporter and a quencher, where the reporter can be equal or different among different probes, are added to the extracted sample-calibrator mixture. Two or more primers may be added to the reaction mixture, depending on the number of variable regions present on the calibrator annealing with the primers. Preferably, up to 3 pairs, more preferably up to two pairs of primers (forward and reverse) are used. Furthermore a thermostable polymerase with 5'-3' nuclease activity is added, thus starting the polymerase/nuclease reaction.

The reaction is carried out in a Sequence Detection System 7700 ABI PRISM that can work both as a DNA amplifier and a collector of fluorescence signals emitted from the reporter markers released upon polymerase nuclease activity. Virtually, three reactions are carried out in parallel, one of them in the presence of target nucleic acid specific probe, one in the presence of the calibrator specific probe/primers, and one in the presence of both.

The reaction in the presence of the target nucleic acid specific probe permits quantitation of the copy number of the extracted target nucleic acid (N_o). The reaction in the presence of the calibrator permits quantitation of the calibrator copy number recovered upon extraction (C_o). The reaction in the presence of both permits calculation of the total number of target templates and calibrator (T).

It is thus possible to calculate the percentage of the calibrator recovery yield R:

$$R = C_o/C,$$

from which the calibration factor (cal)

6

$$cal = 1/R$$

and thus the actual number of nucleic acid units in the sample before extraction are obtained:

$$N = N_o \times Cal$$

5 The relation

$$T = N_o + C_o$$

assures that the amplification efficiency of the standard and calibrator DNA remain identical.

10 The calibrator non-amplification makes it possible to detect any false negatives (technical errors or presence of inhibitors), which represent one of the most important drawbacks when using amplification methods in clinical diagnostics.

 The reaction conditions are the same as those commonly adopted in qPCR reactions (Petrik j. et al., J. Virol. Methods, 64:147-159, 1997).
15 The reaction conditions can be modified in order to compensate for the competition events, more exactly the primer concentration, the polymerase enzyme concentration, the annealing/extension time, or the concentration of cofactors such as $MgCl_2$ can be modified.

 The target nucleic acid can be DNA or RNA, preferably DNA,
20 while primers and probes are preferably deoxyribonucleotide sequences. When the nucleic acid is RNA a previous retro-transcription step is required in order to obtain the corresponding DNA. The probes include a fluorescent reporter label and a quencher label to reduce or to avoid fluorescence from the reporter label when the probes are free in solution.

25 TET (tetrachloro-6-carboxy-fluorescein), JOE (2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein), HEX (hexachloro-6-carboxy-fluorescein) are examples of reporter, preferably TAMRA (6-carboxy-tetramethyl-

rhodamine) and FAM (6-carboxy-fluorescein) are used as quencher and reporter, respectively.

Preferably the 5' end of said probes is in the range of 1 to 30 nucleotides from the 3' end of the forward primer, i.e. at a distance to
5 permit the reporter label release in the absence of nucleic acid polymerization. Preferably, the probes have a blocked 3' end in order to prevent the extension by polymerase, have a T_m higher than the primer T_m , and comprise 18 to 30 nucleotides.

The nucleic acid polymerase is a thermostable polymerase with 5'-
10 3' nuclease activity, preferably a DNA polymerase, and more preferably a DNA polymerase derived from the *Thermus* species.

A great advantage of the described method is represented by the possibility to detect samples containing inhibitors and to mathematically characterize the yield of genetic material extraction. A further advantage
15 is represented by the possibility of simultaneously measuring the calibrator and the target nucleic acid in the same reaction tube. The possibility of detecting total inhibitors of amplification reaction from the samples allows the elimination of false negatives often occurring with known techniques. Moreover, the calibration does not necessitate further
20 standardization which is conversely required, for example, by the TaqMan technique (see Chatellard P. et al., J. Virol. Methods, 71:137-146, 1998).

The present invention also provides a kit to perform the above described method, including, depending on the target nucleic acid, a suitable calibrator, a probe specific for the target nucleic acid, two or
25 more primers and a nucleic acid polymerase.

According to a preferred embodiment, the method of the invention is employed to quantitatively detect the genomic nucleic acid of the HHV-

6, HHV-7, HHV-8, and HIV viruses, in a sample.

Particularly, in the case of HHV-6, the assay is divided into two steps: in the first step gene extraction is performed by a method based on the standard lysis-purification protocol by phenol-chloroform; in the
5 second step the amplification reaction is carried out with specific primers and probes, selected by the "Primer Express" software (Perkin Elmer).

The primer and probe have been designed to amplify both type A and type B HHV-6 strains with the same efficiency. This feature is responsible for very high diagnostic sensitivity.

10 The calibration according to the method of the invention relies on adding to the sample, before DNA extraction, a known amount of a template DNA amplifiable with the same kinetic properties as the HHV-6 amplicon, but at the same time clearly distinguishable from it. A DNA fragment identical to that amplified by the HHV-6 primers, apart from the
15 region complementary to the probe that has been modified so as to preserve the same nucleotide composition but with a random sequence, and with the same melting temperature (T_m), is thus cloned; the obtained plasmid, termed "calibrator", is amplified by the same primers and with the same kinetic as the standard plasmid, but it is revealed by the 7700
20 software only if the PCR mix contains a probe with a sequence complementary to the random sequence.

The calibrator plasmid is expanded and accurately quantitated by the spectrophotometer so as to add an exact amount of it to the samples to be extracted. Upon DNA extraction, samples thus contain a certain
25 number of HHV-6 genomes and calibrator plasmid copies, dependent on the total yield of such an extraction; the HHV-6 DNA quantitation is thus possible, assuming such a yield to be identical for both the molecular

species.

The reaction specific conditions are indicated in further detail in the example section.

To compensate for competition events, the reaction conditions were
5 modified as follow: the primer concentration was elevated ten-fold,
enzyme concentration was doubled, the amplification annealing/extension
was increased by 8 seconds per cycle starting from the initial 60 seconds.
However the competition events between templates narrowed the range of
absolute quantitation (calibrated) from 7 to 5 order of magnitude, 2 above
10 and 2 under the value of the calibrator input, while the relative
quantitation range (non calibrated) and the ability to detect the
experimental false negatives are unchanged.

According to an alternative embodiment, the original calibrator
sequence has been further randomized in the two primers coding regions
15 maintaining the theoretical Tm of the two original primers (as calculated
by the specific software Primer Express PE foster city CA). The relevant
sequences of the new calibrator molecules are reported in Table 2 of the
examples. The target DNA molecule and the calibrator were amplified
with the same kinetics, as evidenced by the following equations:
20 $y = 37.804 + -3.4402 \times \text{LOG}(x)$ $R = 1.000$ for the standard template
amplification, and $y = 38.543 + -3.568 \times \text{LOG}(x)$ $R = 0.998$ for the
calibrator template amplification.

The two molecules added in the same tube were correctly co-
amplified, using standard PCR reactions, for more than 7 order of
25 magnitude with no necessity to compensate for competitive events.

In order to carry out the simultaneous detection and quantification of
target DNA and calibrator in a single tube the calibrator was derivatized at

the 5'end with VIC (Pe Biosystem), a fluorescent molecule having an emission spectrum different from the one used for the target DNA molecule detection.

To eliminate the interference generated by the partial overlapping
5 of the emission spectra of the two dyes, the calibrator PCR conditions were modified by reducing the primers and probe concentrations (final concentration 50nM for both). The reduction of the emission signal of VIC reporter was achieved without modification of the Ct (Cycle threshold) value, thus allowing a reproducible quantitation of the
10 calibrator itself.

The spectral interference was completely avoided by adding the calibrator in a fixed concentration one log higher than the maximal amount of standard used in the reference curve (i.e. 10,000,000 copies of calibrator for a standard curve in which the highest concentration of
15 standard was 1,000,000 copies reaction).

The following examples illustrate the invention in further detail.

EXAMPLES

Example 1

Selection of the HHV-6, HHV-7, HHV-8, HIV, 35s CAMV and
20 Mycobacterial sequences.

The U67 HHV-6 region (A variant, GeneBank Accession N°. X83413) and the 26 HHV-8 orf region (Chang et al., Science 266, 1865-1869, 1994) the HHV-7 region (Gene Bank AF037218), 35sCAMV (Gene Bank AF140604), RegX-SenX (Gene Bank MTY 13628) and 156110
25 (Gene Bank X17848), and the HIV region mapping between the LTR and gag region from nucleotide 684 to 810 using the sequence HXB2CG- Accession number K03455 (Gene Bank) are reported in Table 1 (primers

and probe of the target nucleic acid and calibrator probe). The HHV-6 sequences (primers and probe for the target, calibrator's primers and probe) are reported in Table 2.

The probe sequences of the calibrators (HHV-7, HHV-8, HIV-1, CAMV, Myc. T.) and the calibrator's primers (HHV-6) were designed randomizing the probe region of the standard, while maintaining:

1. the same base composition (G+C/A+T) of the standard
2. an identical T_m (calculated by Perkin Elmer software)
3. an identical length (in order to have the same amplification efficiency)
- 10 4. and being characterized by an absolute absence of homology with the standard (target) in order to avoid cross-hybridization and interferences.

Table 1

HHV-7	Primers	Probes
	Forward	Standard
	5' AGCGGTACCTGTAAATCATCCA3'	5' ACCAGTGAGAAACATCGCTCTAACTGGATCA 3'
HHV-8	Reverse	Calibrator
	5' AACAGAAACGCCACCTCGAT 3'	5' TAAGCCCTGACCGCACGGGTATAATACTAA 3'
HHV-8	Primers	Probes
	Forward	Standard
	5' GTCCAGACGATATGTGGCG3'	5' CATTGGGTATATAGATCAAGTTCCGCCA3'
HHV-8	Reverse	Calibrator
	5' ACTCCAAAATATCGGCCGG3'	5' ACTATTCCATGCGGGAATTTCGAGCATAGTTG3'

(continued)

Table 1 (continued)

HIV-1	Primers	Probes
	Forward	Standard
	5' TACTGACGCTCTCGCACCC 3'	5' ATCTCTCTCTTCTAGCCTCCGGCTAGTCAA 3'
	Reverse	Calibrator
	5' TCTCGACGCAGGACTCG 3'	5' ACTCTCAGCGGCATTCTCCTCACTTCTACT 3'
CAMV	Primers	Probes
	Forward	Standard
	5' GTCTTGCGAAGGATAGTGGGA 3'	5' TGCCTCATCCCTTACGTCAGTGGAGAT 3'
	Reverse	Calibrator
	5' CACGTCTTCAAAGCAAGTGGGA 3'	5' ATCGCTACATGCTAGGCATCTGTGTGC 3'

(continued)

Table 1 (continued)

Myc. T. 1	Primers		Probes
	Forward		Standard
	5' AGGAGGAGTGGCGCTGATG 3'		5' ACGAGGAGTCGCTGGCCGATCC 3'
	Reverse		Calibrator
Myc. T. 2	5' ACTCGGCGAGAGCTGCC 3'		5' TCCAGCGTCAGGCGTAGGCAGC 3'
	Primers		Probes
	Forward		Standard
	5' AGGCGAACCCCTGCCCA 3'		5' TCGACACATAGGTGAGGTCTGCTACCCACA 3'
	Reverse		Calibrator
	5' GATCGCTGATCCGGCCA 3'		5' ACTACGACTACGGCTGCGATCGACATCGAT 3'

Table 2

HHV-6	Primers	Probes
	Forward	Standard
	5' CAAAGCCAAATTATCCAGAGCG 3'	5' CACCAGACGTCACACCCGAAGGAAT 3'
	Reverse	Calibrator
	5' CGCTAGGTTGAGGATGATCGA 3'	5' TACGCAACGCCAACAGACCTAGCGA 3'
Calibrator		
	Primer forward	Probe
	5' CCGGAAACCGAACATTACTGAA 3'	5' TACGCAACGCCAACAGACCTAGCGA 3'
	Primer reverse	
	5' TTACGTGAGGATGATCGAGGC 3'	

Example 2HHV-6 Standard (target nucleic acid) and Calibrator cloning and preparation.

The fragments used for the standard and calibrator DNA
5 construction in the HHV-6 virus detection system are schematically
represented in Figure 1 (1-A and 1-B respectively).

The Standard fragment sequence was obtained by amplification of
the viral DNA from HHV-6 GS strain and subsequent cloning into pCRII
plasmid vector (Invitrogen). The calibrator fragment (133 bp) was
10 chemically synthesized by an Oligosynthetizer (Perkin Elmer), and then
cloned in the same vector as above.

After cloning, both fragments were completely sequenced in order
to identify: i) the identity (co-linearity) of the standard fragment with the
original viral DNA, ii) the identity of the calibrator fragment with the
15 artificially designed sequence.

As shown in Figure 1, the arrows, oriented in the transcription
direction, indicate the oligonucleotide sequence employed as primers. The
dotted line identifies in both constructs the regions of 25 nucleotide used
as the probes (lowercase) differentiating the two constructs, otherwise
20 identical in the remaining 108 nucleotides. These regions, even though
they have the same base composition and a very similar T_m , were
designed in such a way as to function as a heterologous system, allowing
avoidance or minimization of the cross-hybridization events between the
probes employed in the specific fluorimetric detection and the standard
25 and calibrator fragments.

Example 3HHV-6 calibrator/standard system validation

Absence of cross-hybridization

We thus experimentally verified the absence of spurious signals from cross-hybridization. Increasing concentrations of the standard and calibrator fragment (from 101 to 106 plasmid copies per PCR reaction) were measured using the homologue probe (standard probe for the standard DNA, calibrator probe for the calibrator DNA) or the heterologous probe (standard probe for the calibrator DNA, calibrator probe for the standard DNA). Figure 2B shows the detection of the various template amounts employing the probe homologous to the fragment to measure, where: a) indicates the standard amplification curve and, b) the calibrator curve. Detection takes place for both constructs with overlapping kinetics (curves 1-5, a, b) furthermore indicating that the template amplification is proportional to the measured fluorescence signal. The use of heterologous probe (Fig. 2A) for both templates does not generate a signal appreciably higher than the system background noise.

Co-linearity

Amplification co-linearity of the two templates was measured by comparing the two regression line equations generated from the values obtained as threshold cycles as a function of the increasing copy number of the employed template.

The resulting equations are:

$y = 37.804 + -3.4402 \times \text{LOG}(x)$ $R = 1.000$ for the standard template amplification

$y = 38.543 + -3.568 \times \text{LOG}(x)$ $R = 0.998$ for the calibrator template

amplification.

The slope ratio of the two lines is 1.017 thus indicating that the two systems are perfectly overlapping both as amplification efficiency and as fluorimetric detection dynamics.

5 Calibration range

Amplification of the two templates in the same PCR reaction causes an appreciable modification of the amplification curve detected by the system (Fig. 3A). In fact it is possible that for increasing copy amounts, i.e. 500 calibrator copies in unique dose co-amplified in the presence of 0,
10 500, 5,000, 50,000, 500,000 standard copies (from 1a-1e respectively), the fluorescent signal is changed both in the accumulation kinetic and in the final amount of the released product. At the threshold cycle (A' insert), standard template concentrations equivalent to or higher by a Log (A' insert – 1a-1c curves) do not influence the accuracy of the calibrator
15 quantitation. For higher concentrations (1d, 1e curves) the quantitation is partially (marked delay of the threshold cycle, 1d) or completely impaired (1e). The optimization of the PCR conditions, and particularly the combined actions of primer concentration increase (from 300 nM to 3 μ M), doubling the enzyme concentration (from 0.625 to 1.25 AmpliTaq
20 Gold units), and the increase in length of every PCR cycle (8 sec. increment per cycle during the annealing and extension steps), cause an improvement of the amplified product accumulation kinetic and of the final yield of the fluorescence signal (Fig. B, curves 1a-1e). At the threshold cycle (B' insert), standard template concentrations up to 2 Log
25 (50,000 copies) higher than the calibrator input, do not modify its quantitation (B' curves 1e-1d). For higher concentrations (500,000 copies) the fluorimetric signal from the calibrator probe is measurable, although

the lack of signal exponential increase does not allow maintenance of an accurate measure of the calibrator (B' curve 1e).

In opposite conditions (Fig. 4A), i. e. with excess of calibrator up to 2 Log concentration with respect to the standard, (e. g. 500 copies of calibrator vs. 5 copies of standard), the analysis of the reaction kinetics is as above. In particular, in optimized conditions, the quantitation at the threshold cycle (A' insert; "a" indicates the amplification curve of the standard in the absence of the calibrator, "b" the curve measured in the presence of the calibrator), in this case of the standard, is not modified (A' curves 1a-1b: 100 copies of standard and 25 copies of standard concentration, 3a-b: 5 copies of standard concentration).

By means of this optimization it can thus be obtained an accurate quantitation of a template whose amount is unknown, with the following practical advantages:

- 1) Absolute control (both qualitative and quantitative) of the whole process of sample purification and amplification with a dynamic range of at least 5 Log (e. g. 5 to 50,000 copies per reaction);
- 2) Quantitative control of purification and amplification process with a dynamic range of at least 7 logarithms (false negatives due to technical error or to the presence of contaminants inhibiting the PCR reaction).
- 3) Eliminating the unknown sample serial dilution;
- 4) Inserting only one known dose of the calibrator (e. g. 500 copies).

CLAIMS

- 1) A method for the quantitative detection of a nucleic acid (target) from a sample, which comprises the following steps:
 - 5 a) extraction of the nucleic acid from the sample with another nucleic acid (calibrator) previously added to the sample itself, said calibrator having the same sequence of the target nucleic acid, with the exception of one or more regions which in the target nucleic acid hybridize with a probe labeled with a reporter and a quencher,
10 or which hybridize with said probe and in addition with two or more primers, such regions having each other different, randomized nucleotide sequences and a similar T_m , and
 - b) mixing the extracted target nucleic acid and calibrator with primers (forward and reverse) annealing to the corresponding regions on the
15 calibrator and on the target nucleic acid or in addition with primers annealing to the randomized regions on the calibrator, as specified in (a), with probes annealing to the target nucleic acid and to the corresponding randomized region on the calibrator, said probes bearing a reporter and a quencher, and with a nucleic acid
20 polymerase with 5'-3' nuclease activity, in suitable conditions to carry out a polymerization reaction, and
 - c) determination of the signal associated with the reporters released due to the 5' polymerase nuclease activity.
- 2) Method according to claim 1, wherein the calibrator T_m is
25 comprised in the $\pm 4^\circ\text{C}$ range of the target nucleic acid T_m .
- 3) Method according to claims 1-2, wherein the 5' end of the probes is 1 to 30 nucleotides from the 3' end of the forward primer.

- 4) Method according to claims 1-3, wherein the probes have the 3' end blocked in order to prevent the extension by the polymerase.
- 5) Method according to claims 1-4, wherein said nucleic acids, said probes and said primers are DNA sequences, and the nucleic acid polymerase is thermostable DNA polymerase with 5'-3' nuclease activity.
- 6) Method according to claims 1-5, wherein the probes have a T_m higher than that of the primers.
- 7) Method according to claim 6, wherein said probes include 18 to 30 nucleotides.
- 8) Method according to claims 1-7, wherein said probes include a quencher label able to reduce or to avoid the reporter label fluorescence when the probes are free in solution.
- 9) Method according to any of the preceding claims, wherein the target nucleic acid is genomic nucleic acid of the viruses HHV-6, HHV-7, HHV-8 and HIV.
- 10) Method according to claim 9, wherein the virus is HHV-6, the forward primer has the sequence 5' CAAAGCCAAATTATCCAGAGCG 3', the reverse primer the sequence 5' CGCTAGGTTGAGGATGATCGA 3', the target nucleic acid probe the sequence 5' CACCAGACGTCACACCCGAAGGAAT 3', and the calibrator probe the sequence 5' TACGCAACGCCAACAGACCTAGCGA 3'.
- 11) Method according to claim 9, wherein the virus is HHV-7, the forward primer has the sequence 5' AGCGGTACCTGTAAAATCATCCA 3', the reverse primer the sequence 5' AACAGAAACGCCACCTCGAT 3', the target nucleic acid probe the sequence 5' ACCAGTGAGAACATCGCTCTAACTGGATCA 3', and the calibrator probe the sequence 5' TAAGCCCTGACCGCACGGGTATAATACTAA

3'.

12) Method according to claim 9, wherein the virus is HHV-8, the forward primer has the sequence 5' GTCCAGACGATATGTGCGC 3', the reverse primer the sequence 5' ACTCCAAAATATCGGCCGG 3', the
5 target nucleic acid probe the sequence 5' CATTGGTGGTATATAGATCAAGTTCCGCCA 3', and the calibrator probe the sequence 5' ACTATTCCATGCGGAATTTCGAGCATAGTTG 3'.

13) Method according to claim 9, wherein the virus is HIV-1, the
10 forward primer has the sequence 5' TACTGACGCTCTCGCACC 3', the reverse primer the sequence 5' TCTCGACGCAGGACTCG 3', the target nucleic acid probe the sequence 5' ATCTCTCTCCTTCTAGCCTCCGCTAGTCAA 3', and the calibrator probe the sequence 5' ACTCTCAGCGGCATTCTCCTCACTTCTACT 3'.

15 14) Use of a calibrator, as defined in the preceding claims, in a method for the quantitative detection of a nucleic acid sample.

15 15) Kit for the quantitation of a nucleic acid from a sample, comprising one or more calibrators, a probe specific for each target nucleic acid and a probe specific for the calibrator, two or more primers and a thermostable
20 nucleic acid polymerase with 5'-3' nuclease activity.

F i g. 1

(60)

STANDARD PLASMID

CAACGACAA AGCCAATTA TCCAGAGCGG CATCGATATT TAACCTTGT 400
 GTTTCCTGTT TCGGTTTAAAT AGGTCCTGCC GTAGCTATAA ATTGAACAA

A

TTTTTTTtac cagacgctac acccgagga atAACGCTCG TCACAAACAT 450
 AAAAAAAtg gtctgcagtg tgggttctt taTTCCGAGC AGTGTTTGT

 AATATTCCTGT GTAGGCGTTT CGATCATCCT CAACCTAGCG CTCGGGGCTG 500
 TTTTAGACA CATCCGCATA GCTAGTAGGA GTTGGATCGC GAGCCCCCGAC

CALIBRATOR

CAACGACAA AGCCAATTA TCCAGAGCGG CATCGATATT TAACCTTGT 400
 GTTTCCTGTT TCGGTTTAAAT AGGTCCTGCC GTAGCTATAA ATTGAACAA

B

TTTTTTTtac gcaacgcca cagacctagc gaAACGCTCG TCACAAACAT 450
 AAAAAAAtg cgttgcggtt gtctggatcg ctTTCCGAGC AGTGTTTGT

 AATATTCCTGT GTAGGCGTTT CGATCATCCT CAACCTAGCG CTCGGGGCTG 500
 TTTTAGACA CATCCGCATA GCTAGTAGGA GTTGGATCGC GAGCCCCCGAC

Fig. 2




Fig. 2




Fig. 3




Fig. 3





Fig. 4



SEQUENCE LISTING

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> METHOD FOR THE QUANTITATIVE DETECTION OF NUCLEIC ACIDS

<130> hsr

<140>

<141>

<160> 31

<170> PatentIn Ver. 2.1

<210> 1

<211> 23

<212> DNA

<213> HHV-7

<400> 1

agcgggtacct gtaaaatcat cca 23

<210> 2

<211> 20

<212> DNA

<213> HHV-7

<400> 2

aacagaaacg ccacctgat 20

<210> 3

<211> 30

<212> DNA

<213> HHV-7

<400> 3

accagtgaga acatcgctct aactggatca 30

<210> 4

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 4

taagccctga ccgcacgggt ataatactaa 30

<210> 5

<211> 19

<212> DNA

<213> HHV-8

<400> 5

gtccagacga tatgtgcgc 19

<211> 19
<212> DNA
<213> HHV-8

<400> 6
actccaaaat atcggccgg

19

<210> 7
<211> 30
<212> DNA
<213> HHV-8

<400> 7
cattggtggt atatagatca agttccgcc

30

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CALIBRATOR
MODIFIED REGION

<400> 8
actattccat gcggaattcg agcatagttg

30

<210> 9
<211> 18
<212> DNA
<213> HIV-1

<400> 9
tactgacgct ctgcacc

18

<210> 10
<211> 17
<212> DNA
<213> HIV-1

<400> 10
tctcgacgca ggactcg

17

<210> 11
<211> 30
<212> DNA
<213> HIV-1

<400> 11
atctctctcc ttctagcctc cgctagtagtcaa

30

<210> 12
<211> 30
<212> DNA
<213> Artificial Sequence

SEQUENCE LISTING

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> METHOD FOR THE QUANTITATIVE DETECTION OF NUCLEIC ACIDS

<130> hsr

<140>

<141>

<160> 31

<170> PatentIn Ver. 2.1

<210> 1

<211> 23

<212> DNA

<213> HHV-7

<400> 1

agcgggtacct gtaaaatcat cca

23

<210> 2

<211> 20

<212> DNA

<213> HHV-7

<400> 2

aacagaaacg ccacctcgat

20

<210> 3

<211> 30

<212> DNA

<213> HHV-7

<400> 3

accagtgaga acatcgctct aactggatca

30

<210> 4

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 4

taagccctga ccgcacgggt ataataactaa

30

<210> 5

<211> 19

<212> DNA


<213> HHV-8

<400> 5

gtccagacga tatgtgcgc

19

Fig. 4



WO 00/29x

11

11-11-11

11-11-11

11

11-11-11

<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 12

actctcagcg gcattctcct cacttctact

30

<210> 13

<211> 21

<212> DNA

<213> CAMV

<400> 13

gtcttgcgaa ggatagtggg a

21

<210> 14

<211> 21

<212> DNA

<213> CAMV

<400> 14

cacgtcttca aagcaagtgg a

21

<210> 15

<211> 27

<212> DNA

<213> CAMV

<400> 15

tgcgtcatcc cttacgtcag tggagat

27

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 16

atcgctacat gctaggcatc tgtgtgc

27

<210> 17

<211> 19

<212> DNA

<213> Mycobacterium tuberculosis

<400> 17

aggaggagtgc gcgctgatg

19

<210> 18

<211> 17

<212> DNA

<213> Mycobacterium t. 1

actcggcgag agctgcc 17

<210> 19
<211> 22
<212> DNA
<213> Mycobacterium t. 1

<400> 19
acgaggagtc gctggccgat cc 22

<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 20
tccagcgtca ggcgtaggca gc 22

<210> 21
<211> 17
<212> DNA
<213> Mycobacterium t. 2

<400> 21
aggcgaaccc tgcccag 17

<210> 22
<211> 17
<212> DNA
<213> Mycobacterium t. 2

<400> 22
gatcgctgat ccggcca 17

<210> 23
<211> 30
<212> DNA
<213> Mycobacterium t. 2

<400> 23
tcgacacata ggtgaggtct gctaccacaca 30

<210> 24
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

actacgacta cggctgcat cgacatcgat 30

<210> 25
<211> 22
<212> DNA
<213> HHV-6

<400> 25
caaagccaaa ttatccagag cg 22

<210> 26
<211> 21
<212> DNA
<213> HHV-6

<400> 26
cgctagggtg aggatgatcg a 21

<210> 27
<211> 25
<212> DNA
<213> HHV-6

<400> 27
caccagacgt cacacccgaa ggaat 25

<210> 28
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: CALIBRATOR'S
MODIFIED REGION

<400> 28
tacgcaacgc caacagacct agcga 25

<210> 29
<211> 22
<212> DNA
<213> HHV-6

<400> 29
ccggaaaccg aacattactg aa 22

<210> 30
<211> 21
<212> DNA
<213> HHV-6

<400> 30
ttacgtgagg atgatcgagg c 21

WO 00/29613

PCT/EP99/08847

<210> 31
<211> 25
<212> DNA
<213> HHV-6

<400> 31
tacgcaacgc caacagacct agcga

25

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 C12Q1/70		International Application No PCT/EP 99/08847
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GIBSON U E M ET AL: "A NOVEL METHOD FOR REAL TIME QUANTITATIVE RT-PCR" GENOME RESEARCH, US, COLD SPRING HARBOR LABORATORY PRESS, vol. 6, no. 10, 1 October 1996 (1996-10-01), pages 995-1001, XP000642796 ISSN: 1088-9051 the whole document	1-9, 14, 15
A	WOUTENBERG T M ET AL: "QUANTITATIVE PCR BY REAL TIME DETECTION" PROCEEDINGS OF THE SPIE, vol. 2680, 1 January 1996 (1996-01-01), XP000197422 the whole document	1-9, 14, 15
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">27 March 2000</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">04/04/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 051 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Osborne, H</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/08847

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 623 682 A (BECTON DICKINSON CO) 9 November 1994 (1994-11-09) page 5, line 24 - line 34	1-9, 14, 15
A	WO 95 34684 A (UNIV GEORGETOWN) 21 December 1995 (1995-12-21) claims 1-4	1, 9, 13
A	SECCHIERO P ET AL: "QUANTITATIVE PCR FOR HUMAN HERPESVIRUSES 6 AND 7" JOURNAL OF CLINICAL MICROBIOLOGY, US, WASHINGTON, DC, vol. 33, no. 8, 1 August 1995 (1995-08-01), pages 2124-2130, XP000564243 ISSN: 0095-1137 the whole document	9-11
A	KENNEDY MM ET AL: "Identification of HHV8 in early Kaposi's sarcoma: IMPLICATIONS FOR KAPOSI'S SARCOMA PATHOGENESIS" MOLECULAR PATHOLOGY, vol. 51, no. 1, February 1998 (1998-02), pages 14-20, XP000892767 the whole document	1, 9, 12
A	ZIMMERMANN K ET AL: "TECHNICAL ASPECTS OF QUANTITATIVE COMPETITIVE PCR" BIOTECHNIQUES, US, EATON PUBLISHING, NATICK, vol. 21, no. 2, 1 August 1996 (1996-08-01), pages 268-270, 272, 27, XP000597689 ISSN: 0736-6205	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No

PCT/EP 99/08847

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0623682 A	09-11-1994	US 5457027 A	10-10-1995
		AU 675503 B	06-02-1997
		AU 6058094 A	10-11-1994
		CA 2121658 A, C	06-11-1994
		DE 69420454 D	14-10-1999
		DE 69420454 T	23-12-1999
		JP 6343497 A	20-12-1994
		SG 50707 A	20-07-1998
		US 5470723 A	28-11-1995
		US 5561044 A	01-10-1996
		US 5736365 A	07-04-1998
		US 5840487 A	24-11-1998
WO 9534684 A	21-12-1995	AU 692792 B	18-06-1998
		AU 7512394 A	05-01-1996
		JP 10505224 T	26-05-1998